Osteoporosis in Females

Obtain central DXA and interpret T-scores in postmenopausal women. Initiate pharmacotherapy for a hip or vertebral fracture, whether clinically recognized or identified on vertebral imaging, regardless of BMD. A T-score of -2.5 or lower at the femoral neck, total hip, lumbar spine, or 33% radius also supports treatment. acpjournals+1acpjournalsOsteoporosis | Annals of Internal MedicinePubMedThe clinician's guide to prevention and treatment of osteoporosis

For a postmenopausal woman with osteopenia, defined as a T-score between -1.0 and -2.5, calculate US-adapted FRAX using femoral-neck or total-hip BMD when available. A 10-year hip-fracture probability of 3% or greater or major osteoporotic-fracture probability of 20% or greater meets a commonly used treatment threshold. PubMed+1PubMedClinician’s Guide to Prevention and Treatment of OsteoporosisPubMedThe clinician's guide to prevention and treatment of osteoporosis

A proximal humerus, pelvis, or distal forearm fracture in a patient with osteopenia favors treatment; if BMD is not low, individualize according to the fracture mechanism and global risk profile. Reassess fracture risk after every incident fracture because a fracture on or off therapy changes treatment intensity and prompts evaluation for contributors to skeletal fragility. PubMed+1PubMedThe clinician's guide to prevention and treatment of osteoporosisPubMedA Review of Various Clinical Practice Guidelines on Osteoporosis in the Last 5 Years

Before or concurrent with treatment, review for conditions and exposures that alter management: chronic kidney disease, hypercalcemia or hypocalcemia, vitamin D deficiency, hyperparathyroidism, malignancy, and medication-associated bone loss. Initial laboratory assessment can include CBC and serum calcium; abnormalities should trigger disease-directed testing rather than empiric escalation of osteoporosis therapy. acpjournalsacpjournalsOsteoporosis

In chronic kidney disease, obtain DXA plus serum calcium, phosphorus, 25-hydroxyvitamin D, PTH, and kidney-independent bone-turnover markers. In advanced CKD, bone biopsy can directly define turnover, mineralization, and volume when renal osteodystrophy phenotype would alter therapy. Wolters KluwerWolters KluwerManagement of Osteoporosis and Low Bone Mass in Kidney ...

Distinguish routine postmenopausal osteoporosis from CKD-associated mineral and bone disorder before selecting potent antiresorptive treatment in CKD stages 4-5. Drug efficacy and safety data are limited in this population, and denosumab-associated hypocalcemia is a particular safety concern. Wolters KluwerWolters KluwerManagement of Osteoporosis and Low Bone Mass in Kidney ...

For postmenopausal females with primary osteoporosis, ACP recommends a bisphosphonate as initial pharmacologic therapy to reduce fracture risk. Oral bisphosphonates are also identified as first-line treatment in broader osteoporosis guidance; intravenous zoledronate is an alternative when oral administration is not feasible or tolerated. PubMed+1PubMedPharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of PhysiciansNatureEvidence-Based Guideline for the management of ...

Use denosumab as second-line therapy for postmenopausal females with contraindications to or adverse effects from bisphosphonates. Before choosing denosumab, establish that the patient can receive on-time ongoing treatment and can transition to a bisphosphonate if it must be discontinued. PubMed+2PubMedPharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of PhysiciansNatureInsights and implications of sexual dimorphism in osteoporosis | Bone ResearchWolters KluwerPostmenopausal osteoporosis

For females at very high fracture risk, ACP conditionally supports romosozumab or recombinant PTH therapy followed by a bisphosphonate. Sequential therapy is clinically important: BMD declines after romosozumab discontinuation, and an anabolic course should be followed by an antiresorptive agent rather than treated as a stand-alone intervention. PubMed+2PubMedAdditional Background and Contextual Questions 2, 3, and 4 - Screening for Osteoporosis to Prevent Fractures: An Evidence Review for the U.S. Preventive Services Task Force - NCBI BookshelfNatureInsights and implications of sexual dimorphism in osteoporosis | Bone ResearchOxford AcademicACTIVExtend: 24 Months of Alendronate After 18 Months of ...

Match the agent to fracture goal. Alendronate has evidence for hip, vertebral, and nonvertebral fracture prevention; ibandronate has evidence for vertebral-fracture prevention but insufficient evidence for hip-fracture prevention. Raloxifene reduces vertebral but not hip or nonvertebral fracture incidence. PubMedPubMedA Review of Various Clinical Practice Guidelines on Osteoporosis in the Last 5 Years

Monitor oral bisphosphonate adherence actively because dosing complexity and adverse effects commonly undermine persistence. Bone-turnover markers can be measured at baseline and approximately 3 months; a decrease exceeding least significant change, reported as more than 38% for P1NP or more than 56% for CTX, can support adequate antiresorptive response and adherence. NatureNatureEvidence-Based Guideline for the management of ...

Reassess fracture risk after 3-5 years of bisphosphonate treatment and after any new fracture. The decision to continue, pause, or change therapy should incorporate interval fracture, BMD trajectory, adherence, and secondary-cause evaluation rather than duration alone. PubMedPubMedA Review of Various Clinical Practice Guidelines on Osteoporosis in the Last 5 Years

Do not stop denosumab without follow-on bisphosphonate therapy. Denosumab discontinuation is linked to rapid bone loss and increased vertebral-fracture risk, whereas follow-on bisphosphonate therapy is necessary to mitigate this rebound clinical problem. Nature+1NatureInsights and implications of sexual dimorphism in osteoporosis | Bone ResearchWolters KluwerPostmenopausal osteoporosis

Persistent or unexplained BMD loss during therapy should trigger confirmation of adherence and repeat assessment for secondary causes. In advanced CKD, reassess calcium and mineral-metabolism parameters before and during therapies with hypocalcemia risk. acpjournals+1acpjournalsHow Would You Manage This Patient With Osteoporosis?Wolters KluwerManagement of Osteoporosis and Low Bone Mass in Kidney ...